Kiniksa Pharmaceuticals International, plc
KNSA
$31.98
$1.725.68%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 13.80% | 12.44% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 13.80% | 12.44% | |||
| Cost of Revenue | 15.19% | -6.70% | |||
| Gross Profit | 12.67% | 34.86% | |||
| SG&A Expenses | 7.66% | 7.39% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 9.74% | -12.21% | |||
| Operating Income | 51.90% | 168.77% | |||
| Income Before Tax | 46.98% | 191.67% | |||
| Income Tax Expenses | -28.20% | 186.84% | |||
| Earnings from Continuing Operations | 108.83% | 196.07% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 108.83% | 196.07% | |||
| EBIT | 51.90% | 168.77% | |||
| EBITDA | 50.68% | 172.05% | |||
| EPS Basic | 106.64% | 195.61% | |||
| Normalized Basic EPS | 45.41% | 191.27% | |||
| EPS Diluted | 109.09% | 189.50% | |||
| Normalized Diluted EPS | 43.51% | 187.12% | |||
| Average Basic Shares Outstanding | 1.09% | 0.45% | |||
| Average Diluted Shares Outstanding | 2.36% | 5.29% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||